TMB-H patients (TMB≥20 mut/MB) had significantly higher RR (58% vs 20%) and mPFS (12.8 vs 3.3 months) than those with low tumor mutation burden (TMB-L), and there was a positive linear correlation between TMB-H and the efficacy of anti-PD-1/PD-L1 monotherapy (4). This evidence concerns the gene CD274 and neoplasm.